

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representations to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



BBI LIFE SCIENCES CORPORATION

BBI 生命科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1035)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF ACQUISITION OF THE ENTIRE EQUITY INTERESTS OF BIONICS CO., LTD

This announcement is made by BBI Life Sciences Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the recent business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that, on 3 September 2016 (non-trading hours), BBI Asia Limited (“**BBI Asia**”), a wholly-owned subsidiary of the Company, entered into an equity transfer agreement (the “**Agreement**”) with the existing shareholders (the “**Vendors**”) of BIONICS CO., LTD (“**BIONICS**”), a company incorporated in the Republic of Korea (“**South Korea**”), in relation to the sale and purchase of the entire equity interest of BIONICS. Pursuant to the Agreement, BBI Asia will acquire all equity interest in BIONICS held by the Vendors for a total consideration of US\$ 2.40 million. Save for the entering into the Agreement with the Vendors, to the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, the Vendors are independent third parties not connected with the Company and its connected persons and their respective associate.

The Board of the Company is also pleased to announce that, all condition precedents under the Agreement have been satisfied and completion has taken place on 25 October 2016. BIONICS has become an indirect wholly-owned subsidiary of the Company.

General Information of BIONICS

BIONICS is a company incorporated in South Korea. The major products and services of BIONICS are similar to those of the Group, mainly including DNA synthesis, gene sequencing and molecular biology related services. Such products and services have obtained stable customer base and corresponding market share in South Korea. The Group intends to further expand the life sciences products for the research use and services to the South Korea market through BIONICS, enlarge the local market share of the Group, and meanwhile, optimize the portfolio of products and services of BIONICS.

Reasons for and benefit of entering into the Agreement

The Company believes that the acquisition of BIONICS is in line with the established strategy of the Group to expand overseas sales, which is beneficial for the increase of the Group's market share in the overseas markets.

As the applicable percentage ratios of the above-mentioned transaction are lower than 5%, such transaction is exempted from complying with the notification, announcement and shareholders' approval requirements under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is made by the Company on a voluntary basis, for the purpose of informing the investors about the recent business development of the Group.

By order of the Board
BBI Life Sciences Corporation
Wang Qisong
Chairman

Hong Kong, 25 October 2016

As at the date of this announcement, the Board comprises Mr. Wang Qisong, Ms. Wang Luoia and Ms. Wang Jin as executive directors; Mr. Hu Xubo as non-executive director; and Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun as independent non-executive directors.